Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 5, 2023Journal of Medical EconomicsOpen Access

Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

OVOralee J. VarnadoWYWenyu YeXMXiaojuan Mi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Varnado et al. (2023) studied this question.

synapsesocial.com/papers/6a7056745d37378ac1dd6c19https://doi.org/10.1080/13696998.2023.2165365
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study2009 · 304 citations
  2. 2Joint Analysis of Time Use and Consumer Expenditure Data2011 · 33 citations
  3. 3Estimating the Economic Burden of Migraine on US Employers2020 · 59 citations
  4. 4Indirect Cost Burden of Migraine in the United States2007 · 147 citations
  5. 5Trends in utilization and costs of migraine medications, 2017–20202022 · 38 citations